iShares Genomics Immunology and Healthcare ETF (IDNA)
|Ex-Dividend Date||Jun 10, 2021|
|Day's Range||48.83 - 49.92|
|Inception Date||Jun 11, 2019|
The investment seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma IndexTM. The fund generally will invest at least 80% of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20% of its assets in certain futures, options and swap contracts, cash and cash equivalents. The index is composed of developed and emerging market companies that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering. It is non-diversified.
Top 10 Holdings46.94% of assets
|Jun 10, 2021||$0.05215||Jun 16, 2021|
|Dec 14, 2020||$0.03621||Dec 18, 2020|
|Jun 15, 2020||$0.08367||Jun 19, 2020|
|Dec 16, 2019||$0.23706||Dec 20, 2019|
The pandemic has triggered a race to introduce vaccines and treatment options, opening up investment opportunities in the biotech sector.
The genomic-editing space has come under the spotlight with the release of encouraging data from a study assessing an in vivo CRISPR-based gene editing therapy candidate, NTLA-2001.
As investors re-allocate in 2021, it is critical to look past the headlines to the overarching themes that will propel our economy into the future. Investors cannot afford to miss developments like digi...
The coronavirus pandemic triggered a race to introduce vaccine and treatment, thereby opening up new investing opportunities in the biotech sector in 2020.
Megatrends To Invest In Now: 3 Best ETF Picks
BlackRock has identified five big trends that are here to stay for the long haul. Investors can get exposure to these drivers via 17 iShares ETFs.
ETF investors looking ahead to 2021 tend to seek out current trends, but the megatrends run much deeper. These are the large-scale undercurrents that can disrupt a whole sector.
The election year and the coronavirus has highlighted the importance of an adaptive health industry that meets up with quickly changing times. Investors can also tap into this evolution in healthcare th...
The announcement of the 2020 Nobel Prize winners for Chemistry has successfully brought investor attention to the gene-editing space.
The healthcare sector defied last week's market rout buoyed by the progress in the development of a coronavirus vaccine or treatment, and merger and acquisition news.
Per the latest data from an early stage clinical trial, Moderna's experimental coronavirus vaccine is successfully producing neutralizing antibodies and T-cells in older adults.
Small-cap biotech ETFs may prove to be winning bets with or without coronavirus.
From vaccine-related progress to development of cell therapies for the treatment of coronavirus, all kept the rally in the biotech sector alive.
Here we highlight some ETFs for gaining exposure to the genomics market that is currently buzzing with opportunities for investors to cash on.
ETF Edge: Big boost for energy ETF
CNBC's Bob Pisani breaks down the biggest exchange-traded funds moves.
While biotech stocks are often too risky for many investors, with the coronavirus raging and the race for a vaccine in play, taking a look at some ETFs that contain biotech stocks that are making stride...